One of the most discussed topics in the pharmaceutical industry in recent years has been Nitrosamine Contamination. Nitrosamines are compounds with potentially carcinogenic properties, the detection of which has led to large-scale recalls in some drugs worldwide. For this reason, the Nitrosamin Analysis in Drugs according to the International Pharmacopoeias (EP, USP, BP, JP) must be carried out carefully.
What are nitrosamines?
Nitrosamines are chemical compounds that are usually formed by the reaction of secondary amines with nitrites. They may unintentionally arise in industrial processes, in food and in the manufacture of drugs. Since most of these substances can have carcinogenic effects on human health with prolonged exposure, they are strictly controlled by international authorities.
Sources of nitrosamines in medicines
Nitrosamines can occur at different stages of the drug manufacturing process:
- Contamination of raw materials
- Reagents or solvents used in production
- Formation of by-products
- Transfer from packaging materials
- Decomposition during storage and shelf life
These risks have occurred in particular in products such as Antihypertensives of the Sartan Group, Metformin and Ranitidine.
International Standards: EP, USP, BP, JP approaches
In order to prevent nitrosamine contamination worldwide, the pharmaceutical industry is oriented towards four basic sources:
- EP (European Pharmacopoeia): Sets nitrosamine limit values and mandatory validation methods.
- USP (US Pharmacopoeia): Provides guidelines for nitrosamine analysis methods and limit tests.
- BP (British Pharmacopoeia): Contains parallel to the European Pharmacopoeia Quality Control Requirements.
- JP (Japanese Pharmacopoeia): Sets quality and safety standards that require nitrosamine analysis.
The aim of all these standards is to set limits that do not endanger human health and apply reliable methods of analysis.
Why is nitrosamine analysis important?
- Avoidance of cancer risks
- Conformity of approved medicines with international regulations
- Minimizing the recall risk
- Ensuring patient safety
- Manufacturer's reputation and compliance with legal regulations
Nitrosamin analysis is not only a prescribed legal process, but also an important step towards quality assurance in the interest of human health.
Effective drug safety analysis
Drug manufacturers and importers must conduct a Nitrosamine Risk Assessment at each stage of their products and minimize these risks through international standards. Careful nitrosamine tests according to the EP, USP, BP and JP pharmacopoeias ensure both product quality and public health.
If you would like to have nitrosamine analyzes carried out for your medicines or would like more information, you can contact competent and accredited laboratories.